First-in-class Bionaut™ treatment modality will use remote-controlled microscale robots to treat rare pediatric neurological disorder Company also appoints renowned expert in targeted therapeutics and former Kite CEO Aya Jakobovits, Ph.D.,…
The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in…
L.A. Biz recently sat down with CEO Michael Shpigelmacher to discuss the official launch of the company and the technology behind Bionauts. Bionaut Labs has captured the imagination of the…
In this video, Bionaut Labs CEO Michael Shpigelmacher joins Krisztina ‘Z’ Holly from Good Growth Capital for a fireside chat as part of LA MedTech Week. Shpigelmacher discusses the development…
First-in-class Bionaut™ treatment modality uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies locally to targeted brain disease areas $20M financing led by Khosla Ventures supports…
